These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 11497227)

  • 1. The emerging world role of irinotecan in lung cancer.
    Langer CJ
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):15-21. PubMed ID: 11497227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
    Masuda N
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecan.
    Langer CJ
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):19-24. PubMed ID: 11221017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan in advanced lung cancer: focus on North American trials.
    Langer CJ
    Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):17-28. PubMed ID: 15255164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.
    Adjei AA; Argiris A; Murren JR
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):32-40; discussion 41-2. PubMed ID: 10585007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
    Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
    Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
    Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
    J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan therapy for small-cell lung cancer.
    Sandler A
    Oncology (Williston Park); 2002 Apr; 16(4):419-25, 428, 433; discussion 433-4, 437-8. PubMed ID: 12017533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer.
    Fujita A; Takabatake H; Tagaki S; Sekine K
    Cancer Chemother Pharmacol; 2000; 45(4):279-83. PubMed ID: 10755315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
    Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
    Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of topoisomerase I inhibitors in small-cell lung cancer.
    Fukuoka M
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):9-13. PubMed ID: 11497234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical studies of irinotecan alone and in combination with cisplatin.
    Fukuoka M; Masuda N
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S105-11. PubMed ID: 8070018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The global role of irinotecan in the treatment of lung cancer: 2003 update.
    Langer CJ
    Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):30-40. PubMed ID: 12886872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
    Saijo N; Horiike A
    Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):11-6. PubMed ID: 15255163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
    Devore R; Johnson D; Crawford J; Dimery I; Eckardt J; Eckhardt SG
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):79-83. PubMed ID: 9726097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
    Belani CP
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.
    Langer CJ; Somer R; Litwin S; Feigenberg S; Movsas B; Maiale C; Sherman E; Millenson M; Nicoloau N; Huang C; Treat J
    J Thorac Oncol; 2007 Mar; 2(3):203-9. PubMed ID: 17410043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
    Ilson DH
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):22-5. PubMed ID: 15685830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC.
    Natale RB; Socinski M; Sandler A; Israel VP; Miller L
    Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):29-34. PubMed ID: 10981288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current role of irinotecan in the treatment of non-small-cell lung cancer.
    Kelly K
    Oncology (Williston Park); 2002 Sep; 16(9):1153-62, 1165; discussion 1165-6 passim. PubMed ID: 12380945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.